Definium TherapeuticsvsLinde

DFTX and LIN stock compared: price, dividend, valuation and results, from SEC filings.

DFTX

Definium Therapeutics, Inc.

$29.38

Value $4.0B

-2.59%
DFTX's page

Definium Therapeutics (DFTX) has a market value of $4.0B and Linde (LIN) $239B. Over the last year, with dividends, DFTX moved +158.9% and LIN +23.3%. Dividend yield: DFTX none, LIN 1.22%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    DFTX$4.0B

    LIN$239B

    LIN is 59 times DFTX

  • Revenue, 12 months

    DFTX–

    LIN$36.2B

  • Net income, 12 months

    DFTX-$337M

    LIN$7.0B

  • Operating margin

    DFTX–

    LIN25.3%

  • ROIC

    DFTX-35.2%

    LIN11.1%

    46.3 points apart

  • P/E

    DFTX–

    LIN34.1

  • Dividend yield

    DFTX0.0%

    LIN1.2%

    1.2 points apart

  • 5-year return

    DFTX-16.7%

    LIN+65.5%

    82.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

DFTX-16.7%

LIN+65.5%

05010015020222023202420252026
Returns by period
PeriodDFTXWith dividendsLINWith dividends
1 year since November 14, 2025+158.9%Price +158.9%+23.3%Price +21.7%
3 years since November 17, 2023+1,034.4%+124.7% a yearPrice +1,034.4%+31.2%+9.5% a yearPrice +26.3%
5 years since November 16, 2021-16.7%-3.6% a yearPrice -16.7%+65.5%+10.6% a yearPrice +54.7%
10 years since November 17, 2016+577.0%+21.1% a yearPrice +577.0%+422.6%+18.0% a yearPrice +343.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

DFTXDefinium TherapeuticsLINLinde

Valuation

DFTXLIN
Valuation
Price$29.38$515.11
Market value$4.0B$239B
Enterprise value (EV)–$260B
P/E–34.1
P/E, 5-year median–32.6
P/B4.26.1
EV/EBIT–28.4
Free cash flow yield–2.1%

Results and growth

DFTXLIN
Results and growth
Revenue, 12 months–$36.2B
Net income, 12 months-$337M$7.0B
Free cash flow, 12 months-$191M$5.1B
Earnings per share, 12 months-$3.11$15.06
Revenue growth, year on year–3.0%
Revenue growth a year, past–+4.5%over 5 years
EPS growth a year, past–+25.4%over 5 years

Margins and returns on capital

DFTXLIN
Margins and returns on capital
Gross margin–47.9%
Operating margin–25.3%
Net margin–19.3%
ROIC-35.2%11.1%
ROE-64.2%18.1%

Balance sheet

DFTXLIN
Balance sheet
Cash$1.0B$3.9B
Total debt–$25.2B
Net debt / EBITDA–1.7
Interest cover-34.0×35.5×

Dividends and buybacks

DFTXLIN
Dividends and buybacks
Dividend yield–1.2%
Dividend per share, 12 months–$6.30
Dividend growth a year, past–+9.3%over 5 years
Buyback yield–1.9%
Shareholder yield–3.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: DFTX or LIN

Didn't find what you were looking for?

Ask us
Which is bigger, Definium Therapeutics or Linde?

By market value, Linde ($239B) is about 59.3 times Definium Therapeutics ($4.0B), at today's prices.

How did DFTX and LIN stock do over the last 10 years?

Since November 17, 2016, DFTX's price moved +577.0% and LIN's +343.0%. With dividends: DFTX +577.0% (+21.1% a year), LIN +422.6% (+18.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, DFTX or LIN?

The dividend yield at today's price is none for Definium Therapeutics and 1.22% for Linde. Over the last twelve months they paid – and $6.30 per share.

Which is the better investment, Definium Therapeutics or Linde?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.